Ad
related to: new drug to stop pah post hours early- PAH Initiative For HCPs
PAH Initiative Has HCP Resources To
Assess Risk Status & Progression.
- Advancing PAH Care Videos
Watch PAH Experts Discuss Updates
In The 2022 ESC/ERS Guidelines.
- PAH ICD-10 Codes
Access Codes To Classify Diagnoses,
Symptoms, & Procedures For PAH.
- Activin Signaling Pathway
Learn How This Pathway May Be Used
In Combination With Prostacyclin.
- PAH Initiative For HCPs
Search results
Results from the WOW.Com Content Network
Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). [3] [4] Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. [5]
The drug was well tolerated and superior to NO in efficacy and duration. An open-label, non-controlled phase II trial of riociguat in 75 adult patients (42 with CTEPH and 33 with PAH, all in World Health Organization (WHO) functional class II or III) evaluated the safety and tolerability, and the effects on hemodynamics, exercise capacity and ...
Sitaxentan is a small molecule that blocks the action of endothelin (ET) on the endothelin-A (ET A) receptor selectively (by a factor of 6000 compared with the ET B). [3] It is a sulfonamide class endothelin receptor antagonist (ERA) and is undergoing Food and Drug Administration (FDA) review for treating pulmonary hypertension.
For premium support please call: 800-290-4726 more ways to reach us
Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.
Iloprost, sold under the brand name Ventavis among others, is a medication used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, frostbite, and other conditions in which the blood vessels are constricted and blood cannot flow to the tissues. [4] Iloprost is a prostacyclin mimetic. [1]
Those living with PAH should work closely with their healthcare team to manage their disease. Support can be found by calling the American Lung Association HelpLine at 1-800-586-4872 and pressing 2.
Macitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). [5] Macitentan is a dual endothelin receptor antagonist, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ET A and ET B . [ 5 ]
Ad
related to: new drug to stop pah post hours early